Literature DB >> 22954001

Multimodality imaging of pancreatic ductal adenocarcinoma: a review of the literature.

Shailesh V Shrikhande1, Savio George Barreto, Mahesh Goel, Supreeta Arya.   

Abstract

BACKGROUND: Accurate pre-operative imaging in pancreatic cancer helps avoid unsuccessful surgical explorations and forewarns surgeons regarding aberrant anatomy. This review aimed to determine the role of current imaging modalities in the diagnosis and determination of resectability of pancreatic and peri-ampullary adenocarcinomas.
METHODS: A systematic search of the scientific literature was carried out using EMBASE, PubMed/MEDLINE and the Cochrane Central Register of Controlled Trials for the years 1990 to 2011 to obtain access to all publications, especially randomized controlled trials, reporting on the diagnostic accuracy of ultrasonography, multi-detector computed tomography (MDCT), magnetic resonance imaging (MRI), endoscopic ultrasonography (EUS) or positron emission tomography (PET)-computed tomography (CT) and the evaluation of resectability of pancreatic and peri-ampullary adenocarcinomas.
RESULTS: Based on 66 articles analysed in the review, MDCT and MRI/MRCP have comparable sensitivity and specificity rates for diagnosis and staging of pancreatic cancers. EUS offers the best sensitivity and specificity rates for lesions <2 cm. Improved staging has been noted when PET-CT scans are added to pre-operative evaluation.
CONCLUSIONS: MDCT with angiography or MRI/MRCP should constitute the first imaging modality in suspected pancreatic adenocarcinomas. EUS is recommended for assessing lesions not clearly detected, but suspected, on CT/MRI and in tumours considered 'borderline resectable' on MDCT to assess vascular involvement. PET-CT in locally advanced lesions will help rule out distant metastases.
© 2012 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Year:  2012        PMID: 22954001      PMCID: PMC3461371          DOI: 10.1111/j.1477-2574.2012.00508.x

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  86 in total

1.  Regional variations in mortality rates of pancreatic cancer in China: results from 1990-1992 national mortality survey.

Authors:  Ke-Xin Chen; Peizhong Peter Wang; Si-Wei Zhang; Lian-Di Li; Feng-Zhu Lu; Xi-Shan Hao
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

2.  Prediction of vascular involvement and resectability by multidetector-row CT versus MR imaging with MR angiography in patients who underwent surgery for resection of pancreatic ductal adenocarcinoma.

Authors:  Jeong Kyong Lee; Ah Young Kim; Pyo Nyun Kim; Moon-Gyu Lee; Hyun Kwon Ha
Journal:  Eur J Radiol       Date:  2008-12-13       Impact factor: 3.528

Review 3.  Computed tomography in diagnosing vascular invasion in pancreatic and periampullary cancers: a systematic review and meta-analysis.

Authors:  Wen-Yi Zhao; Meng Luo; Yong-Wei Sun; Qing Xu; Wei Chen; Gang Zhao; Zhi-Yong Wu
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2009-10

4.  Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors: influence on patient selection for surgery.

Authors:  Timothy R Donahue; William H Isacoff; O Joe Hines; James S Tomlinson; James J Farrell; Yasser M Bhat; Edward Garon; Barbara Clerkin; Howard A Reber
Journal:  Arch Surg       Date:  2011-07

Review 5.  Identifying relevant studies for systematic reviews.

Authors:  K Dickersin; R Scherer; C Lefebvre
Journal:  BMJ       Date:  1994-11-12

6.  Ultrafast magnetic resonance imaging improves the staging of pancreatic tumors.

Authors:  M Trede; B Rumstadt; K Wendl; J Gaa; K Tesdal; K J Lehmann; H J Meier-Willersen; P Pescatore; J Schmoll
Journal:  Ann Surg       Date:  1997-10       Impact factor: 12.969

7.  Defining a role for endoscopic ultrasound in staging periampullary tumors.

Authors:  M Shoup; P Hodul; G V Aranha; D Choe; M Olson; J Leya; J Losurdo
Journal:  Am J Surg       Date:  2000-06       Impact factor: 2.565

8.  Pancreatic malignancy: value of arterial, pancreatic, and hepatic phase imaging with multi-detector row CT.

Authors:  Joel G Fletcher; Maurits J Wiersema; Michael A Farrell; Jeff L Fidler; Lawrence J Burgart; Takashi Koyama; C Daniel Johnson; David H Stephens; Ellen M Ward; W Scott Harmsen
Journal:  Radiology       Date:  2003-10       Impact factor: 11.105

9.  Utility of 18F-FDG PET/CT for differentiation of autoimmune pancreatitis with atypical pancreatic imaging findings from pancreatic cancer.

Authors:  Tae Yoon Lee; Myung-Hwan Kim; Do Hyun Park; Dong Wan Seo; Sung Koo Lee; Jae Seung Kim; Kyu Taek Lee
Journal:  AJR Am J Roentgenol       Date:  2009-08       Impact factor: 3.959

10.  Comparison between multislice CT and MR imaging in the diagnostic evaluation of patients with pancreatic masses.

Authors:  M Fusari; S Maurea; M Imbriaco; C Mollica; G Avitabile; F Soscia; L Camera; M Salvatore
Journal:  Radiol Med       Date:  2010-01-15       Impact factor: 3.469

View more
  29 in total

Review 1.  Evolution of imaging in rectal cancer: multimodality imaging with MDCT, MRI, and PET.

Authors:  Siva P Raman; Yifei Chen; Elliot K Fishman
Journal:  J Gastrointest Oncol       Date:  2015-04

2.  The value of liver magnetic resonance imaging in patients with findings of resectable pancreatic cancer on computed tomography.

Authors:  Cindy Chew; Patrick J O'Dwyer
Journal:  Singapore Med J       Date:  2016-06       Impact factor: 1.858

3.  The role of 18F-fluorodeoxyglucose positron emission tomography in the management of patients with pancreatic adenocarcinoma.

Authors:  Lujaien A Kadhim; Avani S Dholakia; Joseph M Herman; Richard L Wahl; Muhammad A Chaudhry
Journal:  J Radiat Oncol       Date:  2013-10-30

Review 4.  Endoscopic ultrasound of pancreatic lesions.

Authors:  Charing C N Chong; Raymond S Y Tang; John C T Wong; Anthony W H Chan; Anthony Y B Teoh
Journal:  J Vis Surg       Date:  2016-07-22

5.  Prolonged complete response following gemcitabine-erlotinib combined therapy in advanced pancreatic cancer.

Authors:  Anna M Czarnecka; Piotr Korzeń; Anna Nowak-Dement; Wojciech Kukwa; Jan Korniluk; Cezary Szczylik
Journal:  Oncol Lett       Date:  2015-12-07       Impact factor: 2.967

Review 6.  The Role of Endoscopic Ultrasound in Pancreatic Cancer Staging in the Era of Neoadjuvant Therapy and Personalised Medicine.

Authors:  Miguel Bispo; Susana Marques; Ricardo Rio-Tinto; Paulo Fidalgo; Jacques Devière
Journal:  GE Port J Gastroenterol       Date:  2020-09-07

7.  Vascular endothelial growth factor receptor type 2-targeted contrast-enhanced US of pancreatic cancer neovasculature in a genetically engineered mouse model: potential for earlier detection.

Authors:  Marybeth A Pysz; Steven B Machtaler; E Scott Seeley; John J Lee; Teresa A Brentnall; Jarrett Rosenberg; François Tranquart; Jürgen K Willmann
Journal:  Radiology       Date:  2014-10-14       Impact factor: 11.105

8.  Is tumour size an underestimated feature in the current TNM system for malignancies of the pancreatic head?

Authors:  David Petermann; Nicolas Demartines; Markus Schäfer
Journal:  HPB (Oxford)       Date:  2013-01-29       Impact factor: 3.647

9.  Unexpected benign histopathology after pancreatoduodenectomy for presumed malignancy: accepting the inevitable.

Authors:  Rachel M Gomes; Munita Bal; Shraddha Patkar; Mahesh Goel; Shailesh V Shrikhande
Journal:  Langenbecks Arch Surg       Date:  2016-01-26       Impact factor: 3.445

Review 10.  Imaging diagnosis of pancreatic cancer: a state-of-the-art review.

Authors:  Eun Sun Lee; Jeong Min Lee
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.